Posts by: Diogo Pinto

News

Galinpepimut-S, an experimental cancer vaccine developed by SELLAS Life Sciences, was granted fast track designation by the U.S. Food and Drug Administration for the treatment of multiple myeloma. A therapy candidate is put on a fast ... Read more

April 25, 2018April 25, 2018

Imfinzi, Tremelimumab Combo Benefits Advanced Urothelial Cancer Patients, Phase 1 Trial Data Show

News

An immunotherapy combining an approved and an investigative treatment — Imfinzi (durvalumab) and tremelimumab — showed potential to reduce tumor activity and prolong survival as a second-line therapy in patients with metastatic ... Read more

April 20, 2018April 20, 2018

SD-101 and Keytruda Combo Fights Head and Neck Tumors, Trial Shows

News

A combination of Dynavax Technologies’ immunotherapy SD-101 and Keytruda triggered tumor-fighting responses in a third of patients with an advanced head and neck cancer, a Phase 1b/2 clinical trial showed. The response rate was double the 15 percent ... Read more